HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Solid malignancy in patients who received cyclosporine for fibrosing interstitial pneumonia].

AbstractOBJECTIVE:
Since more solid malignancies are observed in transplant recipients treated with cyclosporine (CsA) than in healthy persons. We sought to describe the incidence of malignancy in patients treated with CsA for fibrosing interstitial pneumonia.
METHODS:
We prospectively reviewed 43 patients who received CsA and prednisolone for fibrosing interstitial pneumonia over 180 days at our hospital between April 2004 and October 2008. The duration of CsA treatment was 632 +/- 364 days.
RESULTS:
Malignancy developed in 6 (14.0%) patients. Time to diagnosis after medical intervention ranged from 394 days to 1325 days (mean, 783 days). Non-small cell lung cancer was diagnosed in 4 cases. These were discovered by routine computed tomography in all cases. Hepatocellular carcinoma and gastric cancer were each diagnosed in 1 case, respectively. Incidence of malignancy tended to be higher in patients who had been treated with CsA for 567 days or more than in those who had been treated for less than 567 days, but this was not statistically significant.
CONCLUSION:
Our results highlight the need for close follow-up for patients who receive CsA for over 2 years. This could lead to cancer detection at an early stage.
AuthorsKodai Kawamura, Kazuya Ichikado, Hiroyuki Muranaka, Yasuhiro Gushima, Norihiro Iwamoto, Makoto Takaki, Tomoya Kuda, Mitsuko Honda, Naoko Arakawa, Moritaka Suga
JournalNihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society (Nihon Kokyuki Gakkai Zasshi) Vol. 48 Issue 4 Pg. 261-6 (Apr 2010) ISSN: 1343-3490 [Print] Japan
PMID20432965 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Calcineurin Inhibitors
  • Steroids
  • Cyclosporine
Topics
  • Aged
  • Calcineurin Inhibitors
  • Cohort Studies
  • Cyclosporine (administration & dosage, adverse effects)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Lung Diseases, Interstitial (drug therapy)
  • Male
  • Middle Aged
  • Neoplasms (chemistry)
  • Prospective Studies
  • Steroids (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: